Redirecting to https://vhio.net/2026/09/10/final-overall-survival-results-of-the-phase-3-matterhorn-study-support-perioperative-immunotherapy-as-a-new-standard-treatment-option-for-resectable-localized-gastric-or-gastroesophageal-junction-can/